Cipla

Stocks to Watch Today: Sammaan Capital, Granules, IndiGo, Corona Remedies, Jubilant Ingrevia, Pace Digitek, Diamond Power, Texmaco Rail in focus on 01 April

Stocks to Watch, 1 Apr: Stocks like Sammaan Capital, Granules India, InterGlobe Aviation, Corona Remedies, Kwality Walls India, Jubilant Ingrevia, Pace Digitek, Jubilant FoodWorks, G R Infraprojects, Swaraj Engines, Diamond Power Infrastructure, Lupin, Coforge, RailTel Corporation of India, and Texmaco Rail and Engineering will be in focus on April 1.

Trade Spotlight: How should you trade PFC, GE Vernova, Bharat Forge, APL Apollo Tubes, DLF, and others on March 19?

The market is expected to be negatively impacted by rising oil prices and concerns over a prolonged pause in the Fed funds rate amid inflation worries. Below are some short-term trading ideas to consider.

Cipla to form JV with Kemwell Biopharma; share price down marginally

Cipla Share Price | The joint venture will undertake the business of developing, applying for and obtaining licenses for, and manufacturing, commercialising, importing and exporting biologic products. It will also engage in licensing or outsourcing any or all of such activities.

Stocks to Watch Today: Hindustan Aeronautics, JSW Cement, Affle, Lupin, Greenlam, Greenply, Tata Motors, Natco Pharma, Reva Diamonds in focus on 4 March

Stocks to Watch, 4 March: Stocks like Hindustan Aeronautics, Dabur India, JSW Cement, Affle 3i, Lupin, HDB Financial Services, Mahindra and Mahindra, Greenlam Indusries, Reva Diamonds, Greenply Industries, Cipla, Capri Global Capital, Tata Motors, and Shalby will be in focus on March 4./

Stocks to Watch Today: UPL, Cipla, Bharti Airtel, Vikram Solar, RailTel Corporation, Highway Infrastructure, IDFC First Bank in focus on 23 February

Stocks to Watch, 23 Feb: Stocks like UPL, Cipla, Vikram Solar, RailTel Corporation of India, Highway Infrastructure, Bharti Airtel, Allcargo Terminals, IDFC First Bank, Sudarshan Pharma Industries, and MIC Electronics will be in focus on February 23.

Neutral Cipla; target of Rs 1310: Motilal Oswal

Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 1310 in its research report dated January 24, 2026.

Brokerage impact: Cipla falls on JPMorgan downgrade to 'neutral'; Syngene hits four-year low after Jefferies' downgrade

Jefferies downgraded Syngene to 'underperform' and slashed price target to Rs 480 from Rs 660; JPMorgan downgraded Cipla to "Neutral" with price target of Rs 1,460 after it reported disappointing Q3 results

Stocks to Watch Today: Tata Steel, Infosys, Gland Pharma, Cipla, HUDCO, Meesho, Adani Green, Angel One, Midwest in focus on 8 January

Stocks to Watch, 8 January: Stocks like Tata Steel, NCL Industries, Infosys, Gland Pharma, Cipla, IRB Infrastructure Developers, Meesho, Adani Green Energy, Angel One, MOIL, and Midwest will be in focus on January 8.

Cipla shares slide 4.5% after USFDA flags compliance gaps at key Lanreotide supplier site

Regulatory action at Pharmathen’s main manufacturing site in Greece could potentially disrupt supplies of one of Cipla’s important complex injectables

Trade Spotlight: How should you trade Titan, Aditya Birla Sun Life AMC, Triveni Engineering, Tata Consumer Products, Emami, and others on December 17?

The market may remain range-bound, with support at the previous week’s low. Below are some short-term trading ideas to consider.

Stocks to Watch Today: Tata Steel, Ashoka Buildcon, Purvankara, Prestige Estates, Cipla, SBI Life Insurance, Luxury Time in focus on 11 December

Stocks to Watch, 11 December: Stocks like Tata Steel, Lloyds Metal and Energy, Ashoka Buildcon, Puravankara, Petronet LNG, Life Insurance Corporation of India, Prestige Estates Projects, Mazagon Dock Shipbuilders, Bank of Baroda, DCM Shriram, KEI Industries, Cipla, State Bank of India, SBI Life Insurance Company, and Luxury Time will be in focus on December 11.

Accumulate Cipla; target of Rs 1,620: Deven Choksey

Deven Choksey recommended accumulate rating on Cipla with a target price of Rs 1,620 in its research report dated November 04, 2025.

Data Story: Cipla shone under Umang Vohra, task cut out for new CEO

Growth in the US business slowed in recent quarters

Accumulate Cipla; target of Rs 1675: Prabhudas Lilladher

Prabhudas Lilladher recommended accumulate rating on Cipla with a target price of Rs 1675 in its research report dated October 31, 2025.

Reduce Cipla; target of Rs 1580: Choice Equity Broking

Choice Equity Broking recommended reduce rating on Cipla with a target price of Rs 1580 in its research report dated October 31, 2025.

Umang Vohra, Cipla’s outgoing CEO says task achieved, ‘not retiring’ from sector

Vohra was the second executive roped in from outside Cipla’s promoter family to lead the drug maker. Under his watch, Cipla saw a sharp improvement in profitability, driven by strategic expansion in chronic therapies, operational efficiencies and global partnerships.

Cipla says Achin Gupta to replace Umang Vohra as Cipla MD, global CEO from April 1; shares fall 4%

This planned transition is in line with our succession process developed by the Board and Umang Vohra, says Cipla

Cipla shares fall 3% after Eli Lilly deal to market weight-loss drug in India: Here's what analysts say

Cipla share price: Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting to profit booking.

Hold Cipla; target of Rs 1570: Deven Choksey

Deven Choksey recommended hold rating on Cipla with a target price of Rs 1570 in its research report dated September 08, 2025.

Buy Cipla; target of Rs 1754: Mirae Asset Sharekhan

Mirae Asset Sharekhan is bullish on Cipla has recommended buy rating on the stock with a target price of Rs 1754 in its research report dated September 02, 2025.

Trade Spotlight: How should you trade TCS, Exide Industries, Cipla, Max Financial Services, Hyundai Motor India, Nykaa, and others on August 26?

The market is likely to consolidate further until it decisively gets back above last Thursday's high. Below are some short-term trading ideas to consider.